Oxandrolone as a Lean-Tissue Anchor in Calorie-Surplus Bulking Cycles
Omega Meds Anavar is an oral Oxandrolone preparation at 10mg per tablet, formulated for athletes who use a mild but anabolically active compound to add dense, low-water-retention lean mass during a structured calorie-surplus phase. Oxandrolone holds a unique position in bulk-cycle planning: it builds dry, quality tissue rather than the glycogen- and water-saturated volume associated with stronger androgens. This distinction makes it a complementary layer within a bulk rather than the primary driver of total weight gain.
Oxandrolone stimulates nitrogen retention in skeletal muscle even under energy surplus conditions, which means each gram of dietary protein is directed more efficiently toward contractile tissue rather than being oxidised. Clinical burn and wasting-disease data — using nitrogen balance methodology — confirm a measurable positive nitrogen balance in Oxandrolone-treated subjects compared to placebo at matched caloric intake. During a bulking cycle, this nitrogen economy accelerates net lean-tissue accrual without the oestrogenic side effects that accompany aromatising androgens at the doses required to match equivalent mass output.
Dosing Architecture for a Lean Bulk Phase
The 10mg tablet unit gives the athlete granular control over weekly dose progression during a bulk. A structured lean-bulk protocol typically assigns Oxandrolone a supporting role at 20–40mg per day alongside a testosterone base, with the Oxandrolone dose held constant or stepped up by one tablet once the base compound has reached steady state — typically after week three. Compared to higher-strength tablet formats, the 10mg unit allows stepwise titration that mirrors how clinical endocrinology protocols manage anabolic agent introduction: one variable changed at a time, with outcomes logged before the next adjustment.
The 100-tablet pack provides sufficient supply to run a full eight-week lean-bulk phase at 20mg per day, or a six-week phase at 30mg per day — both documented community standard ranges for quality-mass applications. Each tablet batch is subject to content-uniformity testing under HPLC methodology, ensuring the declared 10mg strength is consistent across the production run rather than approximated.
Quality Control and Tablet Excipient Profile
Omega Meds produces Anavar within an oral solid-dose manufacturing environment where excipient selection is treated as a functional formulation decision: binders and fillers are chosen for their contribution to tablet hardness, disintegration rate, and API distribution uniformity — not simply as inert volumising agents. The LAL (Limulus Amebocyte Lysate) endotoxin test is a mandatory batch release gate. Microbial contamination limits for total aerobic count and specified pathogens are maintained as defined GMP-aligned release criteria, making the Omega Meds Anavar tablet suitable for the repeat daily administration that a multi-week bulking cycle requires.